Capricor Therapeutics (CAPR) Cash from Investing Activities (2011 - 2026)

Capricor Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$154.6 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 747.29% year-over-year to -$154.6 million in Q1 2026; TTM through Mar 2026 was -$81.1 million, a 2.1% increase from a year earlier, with the FY2025 full-year figure at $97.5 million, up 183.9% from the prior year.
• Cash from Investing Activities retreated to -$154.6 million in Q1 2026 per CAPR's latest filing, from $43.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $43.1 million in Q4 2025 and bottomed at -$154.6 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is $2.0 million (2024), against an average of -$12.0 million.
• Biggest YoY gain for Cash from Investing Activities was 1494.77% in 2022; the steepest drop was 10882.05% in 2022.
• Year by year, Cash from Investing Activities stood at $5.1 million in 2022, then tumbled by 214.01% to -$5.9 million in 2023, then slumped by 2004.53% to -$123.4 million in 2024, then surged by 134.92% to $43.1 million in 2025, then sank by 458.89% to -$154.6 million in 2026.
• Per Business Quant, the three latest CAPR Cash from Investing Activities figures stand at -$154.6 million (Q1 2026), $43.1 million (Q4 2025), and $16.0 million (Q3 2025).